Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
about
Modelling the impact of antiretroviral use in resource-poor settingsEstimating HIV-1 fitness characteristics from cross-sectional genotype dataTwo-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions presentModelling imperfect adherence to HIV induction therapyEstimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscapeA novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Antiretroviral resistance during successful therapy of HIV type 1 infection.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.Longitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy.Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study.The role of therapeutic drug monitoring in treatment of HIV infection.Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice.Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.Current uses and future hopes for clinical pharmacology in the management of HIV infection.Resistance and cross-resistance to abacavir.Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.HIV viral suppression in the era of antiretroviral therapyManaging failure to antiretroviral drugs in HIV-1-infected patients.Early factors in successful anti-HIV treatment.Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failureAtazanavir: new option for treatment of HIV infection.Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.Comparison of sequential three-drug regimens as initial therapy for HIV-1 infectionComparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes.Pediatric HIV infection: immune and viral evaluation.Monotherapy with lopinavir/ritonavir.Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loadsThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoringRecent trends in HIV-1 drug resistance.Mechanism of HIV antiretroviral drugs progress toward drug resistance.Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.Mixed-Effects Models with Skewed Distributions for Time-Varying Decay Rate in HIV Dynamics.Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma.
P2860
Q25255753-3182FD07-EB48-4852-BE66-3E9ABAF7C7D0Q28544753-5B7EAAE0-039B-4340-A1A6-D3084DE83364Q33267067-D9CC3A98-8D3B-4A52-9250-3069A2074F64Q33523201-52B63E29-9C75-4B95-97D7-7860E58C6318Q33648513-60124611-0DAB-42D5-B819-417334624AD4Q33724247-75427EE5-0023-449F-BD3E-63B501464CD9Q33906239-DB184EFF-B323-44C1-B400-52307ECC6286Q33919308-80ACE385-7BAE-4C42-AAE9-84140FA557D3Q33979107-4FE8E35B-98F5-4A65-BB3E-BCF5F9CADBD1Q34084316-0A8DBDA3-3566-40C2-A7BE-FEEF805FFA8EQ34108198-70A17B94-33BD-43BD-BDC8-9315EE009912Q34112020-48718DF4-EDF8-45DD-B5D7-7FBD960825BBQ34229283-FADE6AD4-CC16-4306-8E0E-577979442701Q34340996-A0244CA7-3CF7-4BDA-9C16-D054B2E4283AQ34414078-845858F2-F11A-40F5-B126-D8C5F275C98DQ34459356-4AC601D5-DD37-4A41-A0E6-A24D271ABE86Q34459409-E47317BF-8953-4529-9402-93C160116A7BQ34789834-A578B861-03BC-4C0F-A469-B1CAE70E6B44Q35059337-4A02E53F-135B-4491-A68C-4E1446222F67Q35063764-037798DF-48C5-4B56-A5EF-D0351681C5CDQ35207282-975E62D1-85CB-4E52-9A1D-65211BD59244Q35237575-F8BDA4DD-2B6A-404B-BA8E-CC80B24398BCQ35698801-4A35AE77-988B-4BE7-A619-453625E8D241Q35779915-3B2DB030-725C-4013-8258-385565E20A00Q36240086-E31C97F5-091A-467B-8181-FDD10FC96644Q36374300-83DAE649-08F0-47F6-BA18-97D57A9D5402Q36618299-DFEE8C90-6BC1-45E5-9E53-858006D43727Q36623603-82FED7EB-116C-4A9B-B1BE-2F32AE6E1CB5Q36712414-AE994FA4-39A7-4E0D-8C2B-27F7E955FBF1Q36793648-9EA537F3-13D7-46D4-8E81-6623B1B86BF1Q36802635-FDB341E5-01FD-41FB-A30C-933F1033D05AQ36943833-0FD29699-A767-418A-BC2B-5D8A84982F33Q37018369-B693B0E1-242D-4323-AE26-C2EBBFDEDF23Q37217490-A0D78756-7515-4796-BCAA-5FB1016D7494Q37657560-480EB49C-2B65-4458-BBBE-E2F4A41A2CD4Q37961181-22D53A0F-ABB6-4A62-9866-39BD79F8ECECQ38449098-503EAEA8-A9B8-4AA2-B0D2-AB521A6E1509Q38601241-C8022A1F-BAFC-4BA3-9A2E-B32645E1FFF4Q39459306-52496A7B-37C3-4F22-9E78-EE4721C418CDQ39462036-4D2299CF-FBA4-4EBB-9A25-B93613CEA333
P2860
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Drug susceptibility in HIV inf ...... indinavir-containing regimens.
@en
type
label
Drug susceptibility in HIV inf ...... indinavir-containing regimens.
@en
prefLabel
Drug susceptibility in HIV inf ...... indinavir-containing regimens.
@en
P2093
P356
P1476
Drug susceptibility in HIV inf ...... indinavir-containing regimens.
@en
P2093
A C Collier
C J Petropoulos
D D Richman
D V Havlir
J M Whitcomb
J P Sommadossi
M S Hirsch
N S Hellmann
P304
P356
10.1001/JAMA.283.2.229
P407
P577
2000-01-01T00:00:00Z